Loading...
Market
Will Syndax stock rise more than 10% by end of 2024 following Revuforj® approval?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Stock price data from financial markets such as NASDAQ or NYSE
Story
Syndax Secures FDA Approval for Revuforj®, First Menin Inhibitor for Relapsed Acute Leukemia, Shares Rise 4.3%
Nov 18, 2024, 06:16 PM
Syndax Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for its leukemia treatment, Revuforj® (revumenib). This drug is notable for being the first and only menin inhibitor approved for treating both adult and pediatric patients with relapsed or refractory acute leukemia featuring a KMT2A translocation. The approval marks a significant achievement for Syndax, especially following previous disappointments in other acute leukemia indications. Following the announcement, shares of Syndax ($SNDX) rose by 4.3% in pre-market trading.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 5% growth • 25%
5% to 10% growth • 25%
10% to 20% growth • 25%
More than 20% growth • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
